The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients.

IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE

Clinica e Investigacion en Arteriosclerosis Pub Date : 2024-06-29 DOI:10.1016/j.arteri.2024.04.004

Kung-Hung Lin, Nuria Amigo, Pablo Ortiz, Cristina Alonso, Alexander V Smolensky, Deven Parmar, Naga P Chalasani, Samer Gawrieh

{"title":"The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients.","authors":"Kung-Hung Lin, Nuria Amigo, Pablo Ortiz, Cristina Alonso, Alexander V Smolensky, Deven Parmar, Naga P Chalasani, Samer Gawrieh","doi":"10.1016/j.arteri.2024.04.004","DOIUrl":null,"url":null,"abstract":"Background and aims: Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.Methods: We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.Results: The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.Conclusion: Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica e Investigacion en Arteriosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.arteri.2024.04.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.

Methods: We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.

Results: The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.

Conclusion: Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.

查看原文本刊更多论文

动脉粥样硬化轮廓：用于全面、快速评估动脉粥样硬化参数的新型工具。用于沙格列扎治疗 MAFLD 患者的一个案例。

背景和目的：全面评估药物治疗对影响心血管疾病（CVD）风险的致动脉粥样硬化参数（AP）的影响具有挑战性，因为调节心血管疾病风险的大量参数之间存在相互作用：方法：我们开发了一种说明性工具--动脉粥样硬化轮廓（AC），它结合了加权的主要血脂、脂质和糖蛋白参数，可方便地说明药物治疗后这些参数的整体变化。我们在 EVIDENCES IV 研究中展示了 AC 的适用性，以评估代谢相关性脂肪肝（MAFLD）患者在接受沙格列扎治疗后 AP 的变化：结果：沙格列扎和安慰剂组的基线血浆浓度比一般人群的平均值低。经过16周的治疗后，由于极低密度脂蛋白、甘油三酯和糖蛋白的改变，沙格列扎尔组的AC明显改善：通过 AC，我们可以轻松、全面地评估和观察 AP 的变化。接受沙格列扎治疗后，MAFLD 患者的 AC 有所改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica e Investigacion en Arteriosclerosis PERIPHERAL VASCULAR DISEASE-

CiteScore

3.20

自引率

6.20%

发文量

审稿时长

40 days

期刊介绍： La publicación idónea para acceder tanto a los últimos originales de investigación como a formación médica continuada sobre la arteriosclerosis y su etiología, epidemiología, fisiopatología, diagnóstico y tratamiento. Además, es la publicación oficial de la Sociedad Española de Arteriosclerosis.